The treatment paradigm for prostate cancer patients with biochemical recurrence: Paul Nguyen, MD

Dr. Nguyen on the Role of Radiation Therapy in High-Risk Prostate CancerПодробнее

Testosterone Therapy in Men with Biochemical Recurrence and Metastatic Prostate CancerПодробнее

Intermediate Risk Prostate Cancer: Paul Nguyen, MDПодробнее

Dr. Nguyen on Treatment Considerations in High-Risk Prostate CancerПодробнее

FORMULA-509 rationale + trial design: the addition of AAP + apa post-radical prostatectomyПодробнее

Management of biochemical recurrence in prostate cancerПодробнее

Salvage radiotherapy in biochemically recurrent prostate cancerПодробнее

Strengthening Patient-Provider Relationships in Prostate Cancer TreatmentПодробнее

Enzalutamide Approved for Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MDПодробнее

Dr. Nguyen on Standard and Investigational Treatment Options in High-Risk Prostate CancerПодробнее

Dr. Nguyen on Future Research in High-Risk Prostate CancerПодробнее

SALV-ENZA: SRT + enzalutamide in high-risk PSA-recurrent prostate cancer after radical prostatectomyПодробнее

Evaluation and Management of Recurrent Prostate Cancer Following Radiation TherapyПодробнее

Non-Radical Treatments for Prostate CancerПодробнее

Plan B: Salvage Treatment for Prostate CancerПодробнее

Prostate Cancer | Tanya B Dorff, MDПодробнее

Dr. Einstein on Biochemical Recurrence in Prostate CancerПодробнее

Managing Biochemical Failure After Radiation Therapy: Importance of Both PSA and PSA Doubling TimeПодробнее

Cancer Recurrence After ProstatectomyПодробнее